SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-002665
Filing Date
2022-01-05
Accepted
2022-01-05 16:16:05
Documents
13
Period of Report
2021-12-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d277160d8k.htm   iXBRL 8-K 27162
2 EX-10.1 d277160dex101.htm EX-10.1 259043
  Complete submission text file 0001193125-22-002665.txt   424648

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20211231.xsd EX-101.SCH 2893
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20211231_lab.xml EX-101.LAB 18137
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20211231_pre.xml EX-101.PRE 11408
7 EXTRACTED XBRL INSTANCE DOCUMENT d277160d8k_htm.xml XML 3365
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 22511334
SIC: 2834 Pharmaceutical Preparations